Changes in oxygenation and heart rate after administration of artificial surfactant (ALEC) to preterm infants

J S Ahluwalia, C J Morley

Abstract
To determine if changes in oxygenation and heart rate occur after surfactant, changes in these variables were recorded continuously for 15 minutes before, during, and 15 minutes after the administration of the artificial surfactant ALEC to 21 preterm infants ventilated for respiratory distress syndrome. Median (range) birth weight and gestation were 1199 (561–2680) g and 28 (21–43) weeks, respectively. The mean (SD) time taken for administration was 17-6 (3-8) seconds. No clinically important changes resulted from the administration of ALEC in the mean (SD) values for oxygen saturation (before 91-3 (3-4)%, during 90-7 (3-2)%, after 90-4 (3-7)%) and heart rate (before 143 (15), during 138 (17), after 142 (16)). The maximum change in mean arterial oxygen saturation (Sao2) was a fall of 4-9%.

(Arch Dis Child 1995; 72: F121–F122)

Keywords: ALEC surfactant, oxygenation, heart rate, preterm infants.

Administration of exogenous surfactant to very premature infants with respiratory distress syndrome significantly reduces neonatal mortality.1 There are few data on the immediate effects of giving surfactant to these infants who have labile cardiopulmonary function and tolerate disconnection from the ventilator poorly. There are six preparations in common use, four of which—Exosurf, Survanta, Curosurf and ALEC—have a licence in the United Kingdom. The volumes and techniques of administration are all different. The volumes vary from 5 ml/kg to 1-2 ml/dose. The administration techniques vary: slow instillation at the top of the endotracheal tube over a minimum of four minutes;2 instillation via a catheter to the lower end of the endotracheal tube in four equal proportions with the infant in different positions;3 a rapid bolus of a single dose via a catheter to the lower end of the endotracheal tube followed by hand ventilation with a resuscitation bag;4 and a single rapid bolus via a catheter to the lower end of the endotracheal tube.5

A report of the effect of different dosing techniques with Survanta showed that oxygen saturation and heart rate were reduced during the procedure, regardless of the technique used.3 Dorrepaal et al showed acute increases in cerebral blood flow and oxygenation during delivery of Curosurf, with no change in blood pressure.6 Halliday et al described an increase in oxygenation within 15 minutes of Curosurf administration but did not describe the effect on oxygenation during the administration.4 The Wellcome Foundation also reports a significant incidence of desaturation and bradycardias during dosing with Exosurf.2 Mendoza et al showed significant episodes of desaturation during the administration of both Exosurf and Survanta.7

Methods
This study was conducted in the Rosie Maternity Hospital, Cambridge, where ALEC was given routinely to babies of less than 30 weeks’ gestation as soon as they were intubated after birth. Babies of older gestational ages were also treated with ALEC at intubation if they were at risk of developing respiratory distress syndrome because they were asphyxiated. A second dose was administered at about 1 hour of age if the infant was still intubated and a third dose was given at about 24 hours if the infant remained intubated and ventilated. Further doses were occasionally given to seriously ill infants.

ALEC was administered rapidly as a 1-2 ml bolus through a fine catheter passed to the lower end of the endotracheal tube during a temporary period of disconnection from the ventilator. A rapid 2 ml flush of air was then administered to ensure that no ALEC remained in the catheter.

Oxygen saturation (Sao2), heart rate, intraarterial oxygen tension (Pao2), if available, and airway pressure were recorded on to computer using a data acquisition program (CARDAS, Medical Scientific Ltd, Bedford). Data were recorded continuously for 15 minutes before, during the procedure, and for 15 minutes afterwards.

Ventilator settings and inspired oxygen concentration (FiO2) remained unchanged throughout the period of recording. Because of the difficulty of physiological measurements during acute resuscitation in the delivery unit, these recordings were made on the neonatal unit usually at the time of the third dose of ALEC. Infants studied were selected on the basis of clinically requiring surfactant treatment at the time that recording equipment was available. There was no maximum ventilator pressure or FiO2 level above which infants were excluded from the study.
Table 1  Demographic data

<table>
<thead>
<tr>
<th>Parameter</th>
<th>Median (range)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Gestation (weeks)</td>
<td>28 (25-37)</td>
</tr>
<tr>
<td>Birthweight (g)</td>
<td>1199 (561-2680)</td>
</tr>
<tr>
<td>Age at administration (hours)</td>
<td>26 (21-43)</td>
</tr>
<tr>
<td>Peak inspiratory pressure (cm H2O)</td>
<td>20 (16-40)</td>
</tr>
<tr>
<td>Ventilator rate (per minute)</td>
<td>65 (10-90)</td>
</tr>
<tr>
<td>Fractional inspired oxygen</td>
<td>0.70 (0.30-0.98)</td>
</tr>
</tbody>
</table>

Table 2  Oxygenation and heart rate before, during, and after the administration of ALEC (values are mean (SD))

<table>
<thead>
<tr>
<th></th>
<th>15 minutes before</th>
<th>Difference before–during</th>
<th>During administration</th>
<th>15 minutes afterwards</th>
<th>Difference before–after</th>
</tr>
</thead>
<tbody>
<tr>
<td>Oxygen saturation %</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=21)</td>
<td>91.3 (3.4)</td>
<td>0.68 (SE 0.41)</td>
<td>90.7 (3.2)</td>
<td>90.4 (3.77)</td>
<td>0.90 (SE 0.39)</td>
</tr>
<tr>
<td>Heart rate per minute</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>(n=21)</td>
<td>143 (15)</td>
<td>4.72 (SE 2.62)</td>
<td>138 (17)</td>
<td>142 (16)</td>
<td>0.12 (SE 0.85)</td>
</tr>
<tr>
<td>Intra-arterial oxygen</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>tension kPa (n=12)</td>
<td>7.9 (1.1)</td>
<td>0.37 (SE 0.19)</td>
<td>7.5 (1.3)</td>
<td>7.6 (1.5)</td>
<td>0.29 (SE 0.23)</td>
</tr>
</tbody>
</table>

Results

Twenty one infants were studied. Their demographic data are shown in table 1. Although the intention was to keep the Fio2 unchanged throughout the period of recording, one infant desaturated acutely following surfactant administration and required a significant increase in Fio2 from 0.40 to 0.80. For the other 20 infants the Fio2 was unchanged.

The time taken to administer ALEC was determined from the recording of airway pressure as being the time the endotracheal tube was disconnected from the ventilator. The mean time taken to administer ALEC was 17.6 (SD 3.8) seconds with a minimum of 12 and a maximum of 26 seconds. The mean values for Sao2, heart rate, and Pao2 were calculated for each baby and for each time period. For the group as a whole, there were no clinically important differences in these parameters among the three time periods (table 2). Only the difference between the pre- and postadministration Sao2 reached significance (p=0.03). The maximum change in the mean Sao2 for any baby, comparing the periods before and after surfactant administration, was a fall of 4.8%. A similar maximum fall of 4-7% was seen in the mean Sao2 comparing the periods before and during surfactant delivery. Accompanying maximum changes in heart rate for these periods were falls of 39 and 10 beats per minute, respectively. No infant had a mean heart rate below 99 beats per minute during any period.

Discussion

The changes in oxygenation and heart rate associated with the administration of ALEC compare favourably with the changes reported during the administration of Exosurf,2 where 22% of infants experienced a fall of at least 20% in oxygen saturation. In the study by Zola et al using Survanta, falls in Sao2 of around 10% were commonly seen, with accompanying falls in heart rate of the order of 40 beats per minute.3 Mendoza et al, looking at changes associated with the administration of Exosurf and Survanta, showed that infants spent nearly 25% of the time during dosing with an oxygen saturation of less than 85%, regardless of which surfactant was used.3 Horbar et al, in a study comparing outcome using Exosurf and Survanta, noted oxygen saturations of less than 85% in 46% and 35% of infants, respectively, during administration of Exosurf and Survanta.6

The typical tidal volume for this group of infants in the acute stage of respiratory distress syndrome will be 6 to 15 ml/kg — that is, between 7 and 10 ml. The recommended volume of saline in which ALEC should be mixed for administration is 1.2 ml, representing 12–17% of the tidal volume for this group. This compares with volumes of up to 5 ml/kg for other surfactants, representing up to 85% of the tidal volume. The relatively small fall in oxygen saturation seen during ALEC administration may therefore be related to the small volume and consequently short disconnection time.

This study has shown that ALEC can be given rapidly to preterm infants with respiratory distress syndrome without clinically important changes in oxygenation or heart rate during or immediately after its administration.

JSA is funded by Wellbeing. ALEC was donated by Britannia Pharmaceuticals Ltd, Redhill, Surrey, England.

Changes in oxygenation and heart rate after administration of artificial surfactant (ALEC) to preterm infants.

J. S. Ahluwalia and C. J. Morley

Arch Dis Child Fetal Neonatal Ed 1995 72: F121-F122
doi: 10.1136/fn.72.2.F121

Updated information and services can be found at:
http://fn.bmj.com/content/72/2/F121

These include:

Email alerting service
Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/